Obinutuzumab targets CD20 on B cells; its Fc engages Fcγ receptors (e.g., CD16) on effector cells to mediate ADCC/ADCP, killing CD20+ B cells. Cells expressing CD16B act as effectors, not targets, and are not directly killed.